[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100607947":3},{"organization":4,"armGroups":7,"interventions":35,"overallOfficials":41,"centralContacts":45,"locations":51,"responsibleParty":66,"collaborators":41,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":41,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":41,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":41,"overallStatus":54,"whyStopped":41,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Marea Therapeutics","INDUSTRY",[8,15,19,23,27,31],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose A MAR002","EXPERIMENTAL","Subcutaneous injection",[13,14],"Drug: MAR002","Drug: Placebo",{"label":16,"type":10,"description":17,"interventionNames":18},"Dose B MAR002","Cohort 2 receiving single Dose B",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Dose C MAR002","Cohort 3 receiving single Dose C",[13,14],{"label":24,"type":10,"description":25,"interventionNames":26},"Dose D MAR002","Cohort 4 receiving single Dose D",[13,14],{"label":28,"type":10,"description":29,"interventionNames":30},"Dose E MAR002","Cohort 5 receiving single Dose E",[13,14],{"label":32,"type":10,"description":33,"interventionNames":34},"Dose F MAR002","Cohort 6 receiving multiple Dose F",[13,14],[36,42],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"DRUG","MAR002","subcutaneous injection",[9,16,20,24,28,32],null,{"type":37,"name":43,"description":11,"armGroupLabels":44,"otherNames":41},"Placebo",[9,16,20,24,28,32],[46],{"name":47,"role":48,"phone":49,"phoneExt":41,"email":50},"Andrew Lane","CONTACT","415-766-3610","mar-201-info@mareatx.com",[52],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":41},"Marea Site","RECRUITING","Tempe","Arizona","85283","United States","US",{"type":61,"coordinates":62},"Point",[63,64],-111.90931,33.41477,{"lat":64,"lon":63},{"type":67,"investigatorFullName":41,"investigatorTitle":41,"investigatorAffiliation":41,"oldNameTitle":41,"oldOrganization":41},"SPONSOR","100607947","phase-1-study-of-mar002-in-healthy-men-100607947",false,"NCT07195175","Study of MAR002 in Healthy Men","First in Human, Randomized, Blinded, Placebo-Controlled Single Ascending Dose and Multiple Dose Study of MAR002 in Healthy Men","Inclusion Criteria:\n\n1. Willingness to provide written informed consent\n2. Age 18 to 40\n3. Weight 55 to 95 kg\n4. Body mass index (BMI) 18 to 30 kg\u002Fm2\n5. Healthy men\n\nExclusion Criteria:\n\n1. History of hypersensitivity to monoclonal antibodies or study drug\n2. Participation in any other investigational drug study\n3. History of cancer\n4. Recent acute illness\n5. Positive test for HIV, hepatitis B\u002FC\n6. History of substance abuse or nicotine use\n7. Recent blood donation\n8. History of pituitary disorder\n9. Any condition that prevents the participant from complying with study procedures",true,"MALE","18 Years","40 Years",{"count":80,"type":81},45,"ESTIMATED","INTERVENTIONAL",[84],"PHASE1","Evaluate the safety and tolerability of subcutaneous (SC) administration of MAR002 in healthy men",[87],"Acromegaly","2026-01-08",{"date":90,"type":91},"2026-01-12","ACTUAL",{"date":93,"type":91},"2025-08-11",{"date":95,"type":81},"2026-07",{"name":5,"class":6},1]